Neurology Central

Alzheimer’s medical drink fails primary endpoint, but shows promise for slowing cognitive decline

Results from the European LipiDiDiet clinical trial investigating the effectiveness of a medical drink proposed to benefit mild Alzheimer’s disease (AD) dementia were today published online in The Lancet Neurology. While primary endpoints were not met, the drink did show a stabilization in cognitive performance and reduced brain shrinkage.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.